Australia In Vitro Diagnostics (IVD) Market Outlook to 2030
By Technology, By Application, By End User, By Testing Location, and By Region
Report Overview
Report Code
TDR0223
Coverage
Asia
Published
August 2025
Pages
80
Flexible Purchase Options
Select and purchase only the chapters you need for your strategic decisions
On This Page
Report Overview
Executive summary will be available soon.
Report Coverage
Verified Market Sizing
Multi-layer forecasting with historical data and 5–10 year outlook
Deep-Dive Segmentation
Cross-sectional analysis by product type, end user, application and region
Competitive Benchmarking & Positioning
Market share, operating model, pricing and competition matrices
Actionable Insights & Risk Assessment
High-growth white spaces, underserved segments, technology disruptions and demand inflection points
Review Methodology & Data Structure
Preview report structure, data sources and research framework
Executive Summary
Explore Flexible Purchase Options or Have Limited Budget?
Pay only for relevant chapters • Customizable report sections
Table of Contents
Choose individual sections to purchase. Mix and match as you like.
3.1. Public Pathology Networks (NSW Health Pathology, PathWest, SA Pathology, Pathology Queensland, etc.)
3.2. Private Laboratory Groups (Sullivan Nicolaides, Douglass Hanly Moir, Australian Clinical Labs, Sonic Healthcare, etc.)
3.3. Distributors and Sponsors (Local IVD Sponsors, ARTG License Holders)
3.4. Regulatory Bodies (TGA, NATA/RCPA, NPAAC)
3.5. Technology Providers & OEMs
3.6. Procurement Agencies (HealthShare NSW, HSV, QLD Health Procurement)
4.1. Delivery Model Analysis for IVD Testing in Australia-Central Lab, Hub-and-Spoke, Near-Patient, PoCT, Self-Testing [Margins, Adoption Rates, Turnaround Time Strengths/Weaknesses, Infrastructure Costs]
4.2. Revenue Streams for Australia IVD Market-Reagent Sales, Instrument Capital Sales, Managed Service Agreements, Reagent-Rental Models, Service & Maintenance, Software Licenses
4.3. Business Model Canvas for Australia IVD Market-Value Proposition, Customer Segments, Key Activities, Revenue Model, Cost Structure, Key Partners, Customer Relationships
5.1. Public vs Private Pathology Market Share [By Volume, By Revenue, By Technology]
5.2. Investment Models in Australia IVD Market [State-Funded, Private Capital, Public-Private Partnerships]
5.3. Comparative Analysis of Test Funnel Processes in Public vs Private Labs [From Collection to Reporting, TAT Benchmarks, Connectivity Standards]
5.4. Pathology Budget Allocation by Hospital Size / Health Network
8.1. Revenues, 2019-2024
8.2. Volume of Tests Processed, 2019-2024
9.1. By Market Structure (Public vs Private Pathology Labs)
9.2. By Technology (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Haematology, Microbiology, PoCT)
9.3. By Application (Infectious Disease, Oncology, Cardiometabolic, Endocrinology, AMR/AMS)
9.3.1. By Type of Molecular Diagnostic Testing (PCR, NAAT, NGS)
9.3.2. By Type of Infectious Disease Testing (Respiratory, STIs, GI Panels, TB)
9.3.3. By Type of Oncology Testing (Companion Diagnostics, Liquid Biopsy, Tumour Profiling)
9.3.4. By Type of PoCT (HbA1c, CRP, Troponin, COVID-19 RATs)
9.4. By End-User (Public Hospital Labs, Private Labs, GP/ACCHS PoCT, Pharmacies, Home-Testing)
9.5. By Testing Location (Core Labs, Hub Labs, Near-Patient, Home/Self)
9.6. By Procurement Channel (State Tenders, Direct Purchase, Distributor Contracts)
9.7. By Open vs Proprietary Systems (Closed Analyser Ecosystems vs Open-Platform Devices)
9.8. By Region/State (NSW, VIC, QLD, WA, SA, TAS, ACT, NT)
10.1. Lab Client Landscape and Cohort Analysis (Public Networks, Private Groups, Specialist Clinics)
10.2. Decision-Making Process for IVD Procurement (Technical, Financial, Regulatory, TGA Compliance)
10.3. Testing Program Effectiveness and ROI Analysis (Screening Programs, PoCT Programs)
10.4. Diagnostic Gap Analysis Framework (Under-Tested Populations, Turnaround Delays, Regional Coverage Gaps)
11.1. Trends and Developments for Australia IVD Market [Syndromic Testing, Managed Equipment Services, AI Integration]
11.2. Growth Drivers [Aging Population, Screening Program Expansions, AMR Programs]
11.3. SWOT Analysis for Australia IVD Market
11.4. Issues and Challenges [Workforce Shortages, Tender Price Compression, Supply Chain Risks]
11.5. Government Regulations [TGA IVD Classes, ARTG Listing, NATA Accreditation, MBS Pathology Reimbursement]
12.1. Market Size and Future Potential for PoCT and Self-Testing Devices
12.2. Business Model and Revenue Streams in PoCT Supply
12.3. Delivery Models and Test Menu Offered (Primary Care, Pharmacies, Hospitals)
12.4. Cross-Comparison of Leading PoCT Players [Company Overview, ARTG Listings, Revenues, Installed Base, Menu Breadth, Service Network, Connectivity, Pricing]
15.1. Market Share of Key Players in Australia IVD Market (Revenue & Installed Base)
15.2. Benchmark of Key Competitors [Company Overview, USP, Business Strategies, Business Model, Installed Base, Revenues, Pricing, Technology Used, Test Menu, Major Clients, Tender Wins, Strategic Partnerships, Recent Developments]
15.3. Operating Model Analysis Framework (Public vs Private Lab Supply Models)
15.4. Gartner Magic Quadrant for IVD Suppliers in Australia
15.5. Bowmans Strategic Clock for Competitive Advantage in IVD Market
16.1. Revenues, 2025-2030
16.2. Projected Volume of Tests, 2025-2030
17.1. By Market Structure (Public vs Private Pathology Labs)
17.2. By Technology (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Haematology, Microbiology, PoCT)
17.3. By Application (Infectious Disease, Oncology, Cardiometabolic, Endocrinology, AMR/AMS)
17.3.1. By Type of Molecular Diagnostic Testing
17.3.2. By Type of Infectious Disease Testing
17.3.3. By Type of Oncology Testing
17.3.4. By Type of PoCT
17.4. By End-User (Public Hospital Labs, Private Labs, GP/ACCHS PoCT, Pharmacies, Home Testing)
17.5. By Testing Location (Core Labs, Hub Labs, Near-Patient, Home/Self)
17.6. By Procurement Channel (State Tenders, Direct Purchase, Distributor Contracts)
17.7. By Open vs Proprietary Systems
17.8. By Region/State (NSW, VIC, QLD, WA, SA, TAS, ACT, NT)
Discuss a Customized Research Scope
Custom research scope • Tailored insights • Industry expertise
Research Methodology
Step 1: Ecosystem Creation
We map the full Australia In Vitro Diagnostics (IVD) Market ecosystem across demand- and supply-side entities. Demand side includes public pathology networks (e.g., NSW Health Pathology, Pathology Queensland, SA Pathology, PathWest, ACT Health, NT Health), private laboratory groups and their collection-centre networks, day hospitals and specialist clinics, GP practices and Aboriginal Community Controlled Health Services (PoCT), pharmacies (self/near-patient testing), national screening program operators/registries, and payors (Department of Health and Aged Care via MBS). Supply side spans IVD OEMs and local sponsors/distributors, reagent and consumable makers, middleware/LIS vendors, service providers, logistics/cold-chain partners, and EQA/proficiency bodies. From this map we shortlist 5–6 leading suppliers based on Australia-specific criteria: ARTG breadth and TGA class coverage, installed analyser base and service density by state/territory, tender footprint with state procurement hubs, reliability KPIs (uptime/TAT support), and disclosed ANZ revenues where available. Sourcing draws on government portals, statutory databases, industry articles, multiple secondary repositories, and proprietary databases to collate ecosystem-level intelligence.
Step 2: Desk Research
We conduct exhaustive desk research using primary-source, audit-ready repositories to assemble market- and company-level evidence. Core datasets include: TGA’s ARTG for approved IVDs and sponsor obligations; MBS Online and departmental releases for item utilisation and policy updates; AIHW for health system activity and screening program outputs; ABS for population and labour statistics; NATA/RCPA directories for laboratory accreditation; state procurement portals (e.g., HealthShare NSW, HealthShare Victoria, Queensland Government QTenders) and AusTender for award histories; RCPAQAP for EQA participation categories; and company-filed annual reports/press releases for Australia-specific operations. We aggregate insights on installed bases, menu coverage, connectivity (HL7/FHIR), logistics requirements, staffing mix, and service models (managed service, reagent-rental, capital placements). This corpus becomes the foundation for segment sizing, competitive mapping, and value-chain diagnostics.
Step 3: Primary Research
We run structured interviews with C-suite and operational leaders across public networks and private labs (pathology directors, procurement leads, PoCT coordinators), IVD manufacturers (ANZ managing directors, service leaders, medical affairs), distributors/logistics partners, and policy stakeholders. Objectives: validate hypotheses from desk work, authenticate utilisation patterns and service levels, and capture operational details (installation timelines, middleware integrations, QC/EQA workflows, field-service coverage, training). A bottom-to-top approach estimates vendor revenues from installed bases and reagent pull-through coefficients at the assay family level; these are rolled up to market views and reconciled with utilisation from Medicare and screening programs. To further verify operating claims (lead times, SLAs, support scope), we perform blind-buyer exercises with multiple suppliers and labs, cross-checking responses against tender documents, accreditation records, and regulatory filings. Where feasible, we complement interviews with site walk-throughs of core labs, hub/satellite nodes, and PoCT hubs to observe workflow, automation, and TAT controls.
Step 4: Sanity Check
We execute top-down and bottom-up reconciliations to test internal consistency. Top-down anchors include Medicare pathology utilisation and AIHW screening/testing activity, adjusted for inpatient/outpatient mix and non-reimbursed testing. Bottom-up models aggregate volumes by modality (clinical chemistry, immunoassay, molecular, haematology, microbiology/ID-AST, coagulation, urinalysis, PoCT) using installed-base counts, average runs, and validated reagent-per-test factors. We triangulate with accreditation footprints (NATA/RCPA), procurement awards, and OEM service coverage by state. Sensitivity analyses probe key levers—menu mix shifts, automation adoption, and hub-and-spoke consolidation—and gap analyses flag any variance beyond tolerance bands, triggering targeted re-interviews or source re-checks. The output is a traceable, audit-ready dataset and narrative suitable for board-level decision-making and tender strategy.
See What's Inside the Report
Get a preview of key findings, methodology and report coverage
Frequently Asked Questions
What is the potential for the Australia In Vitro Diagnostics (IVD) Market?
The Australia In Vitro Diagnostics (IVD) Market shows strong potential as healthcare systems deepen screening programs, expand precision oncology, and push diagnostics closer to the patient through point-of-care and connected home testing. Robust public funding, a high test-utilization culture, and continued digitalization of lab workflows underpin sustained demand across core lab and molecular modalities. Ongoing investments in automation, data connectivity, and quality frameworks further position the market for reliable long-term expansion.
Who are the key players in the Australia In Vitro Diagnostics (IVD) Market?
The Australia In Vitro Diagnostics (IVD) Market features global majors and innovative domestic firms. Leading suppliers include Roche Diagnostics, Abbott, Siemens Healthineers, Danaher (Beckman Coulter and Cepheid), BD, bioMérieux, Sysmex, QIAGEN, Thermo Fisher Scientific, Hologic, QuidelOrtho, Illumina, and Bio-Rad. Notable Australian players include Genetic Signatures and SpeeDx. These companies stand out for their broad test menus, installed analyzer bases, nationwide service coverage, and deep integration with public and private pathology networks.
What are the growth drivers for the Australia In Vitro Diagnostics (IVD) Market?
Key growth drivers include rising test intensity from chronic and infectious diseases, national screening programs (e.g., bowel and cervical), and accelerating adoption of molecular and syndromic panels. Investment in lab automation and middleware, wider use of point-of-care testing across primary care and remote communities, and expanding companion diagnostics in oncology all add momentum. Interoperability initiatives and analytics/AI for interpretation and workflow optimization further support performance and clinical utility.
What are the challenges in the Australia In Vitro Diagnostics (IVD) Market?
The market faces pricing pressure from selective Medicare Benefits Schedule indexation and large-scale state tenders, which compress margins while demanding high service levels. Workforce shortages among medical scientists and pathologists strain throughput and specialized coverage, especially in regional areas. Integration and interoperability gaps between LIS, middleware, and national digital health platforms can complicate deployments. Supply-chain resilience, QA/EQA compliance, and managing legacy analyzer footprints also remain ongoing operational hurdles.
License Options
PDF + Excel
Complete report package
$4,000
Excel Only
Data and analytics
$2,500
Custom Sections
Starts from $100
$0